GRAND PHARMACEUTICAL Aktie

>GRAND PHARMA Aktienkurs

0.8 EUR (TradegateBSX)

Ask: 0.825 EUR / 3622 Stück

Bid: 0.775 EUR / 3890 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

GRAND PHARMA Aktie über LYNX handeln

Intraday

1 Jahr

>GRAND PHARMA Performance

1 Woche: +4,6%

1 Monat: -0,3%

3 Monate: -5,6%

6 Monate: -13,7%

1 Jahr: +8,8%

laufendes Jahr: -8,0%

>GRAND PHARMACEUTICAL Aktie

Name:

GRAND PHARMACEUTICAL GROUP

Land:

Hong Kong (China)

Sektor:

Gesundheit

ISIN/ Wkn:

BMG210A71016 / A0Q8LD

Symbol/ Ticker:

MX6A (Frankfurt)

Kürzel:

FRA:MX6A, ETR:MX6A, MX6A:GR

Index:

Webseite:

http://www.chinagrandphar..

Profil:

Grand Pharmaceutical Group Limited is a diversified pharmaceutical company operating in the healthcare sector. Its primary function is the development, manufacture, and sale of medication and healthcare products. Known for its extensive portfolio, th..
>Volltext..

Marktkapitalisierung:

2804.39 Mio. EUR

Unternehmenswert:

3110.05 Mio. EUR

Umsatz:

1366.97 Mio. EUR

EBITDA:

241.08 Mio. EUR

Nettogewinn:

138.09 Mio. EUR

Gewinn je Aktie:

0.04 EUR

Schulden:

525.54 Mio. EUR

Liquide Mittel:

129.64 Mio. EUR

Operativer Cashflow:

Bargeldquote:

0.29

Umsatzwachstum:

-7.19%

Gewinnwachstum:

-55.77%

Dividende je Aktie:

0.03 EUR

Dividendenrendite:

3.83%

Dividendenschätzung:

2.58%

Div. Historie:

14.04.25 - 0.0287144€
06.06.24 - 0.0287144€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

GRAND PHARMACEUTICAL, GRAND PHARMA

Letzte Datenerhebung:

06.04.26

>GRAND PHARMA Kennzahlen

Aktien/ Unternehmen:

Aktien: 3501.81 Mio. St.

Frei handelbar: 30.03%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: 12614

Umsatz/Mitarb.: 0.11 Mio. EUR

Analysten:

Analystenrating: No rating

Kursziel: -

Bewertung:

KGV: 21.03

KGV lG: 11.17

KUV: 1.96

KBV: 1.53

PEG-Ratio: -

EV/EBITDA: 12.9

Rentabilität:

Bruttomarge: 55.2%

Gewinnmarge: 10.1%

Operative Marge: 12.9%

Managementeffizenz:

Gesamtkaprendite: 4.76%

Eigenkaprendite: 7.41%

>GRAND PHARMA Peer Group

Gesundheit

>GRAND PHARMA Chart & Kurs - Tradegate

>GRAND PHARMA News

25.03.26 - 11:45	Grand Pharmaceutical Obtains Approval in China for Phase II Clinical Trial of TCM Class 1 Innovative Drug GPN01020 (AAStocks)
	Grand Pharmaceutical (00512.HK) announced that the group's traditional Chinese medicine (TCM) innovative drug GPN01020, intended for the preventive treatment of migraines, has recently received approval from the National Medical Products Administration to commence a Phase II clinical trial.This study is a randomized, double-blin......

23.02.26 - 09:51

XFRA: MWBMU - HANDELSUNTERBRECHUNG - TEIL 6 (XETRA)

SE0016797773 US5904794089 KYG8879R1048 GB00B0WJ3L68 US4385651033 US6067694041 US83600C3016 US5797801074 US60272J1034 KYG1821D1097 US6025663096 US5949728878 US5949728795 US5949728613 US5949728530 US60649T1079 KYG9891U1334 US74767N1072 CA57773Y2096 US14167R3084 US6067991041 MX01AM050019 BMG210A71016 AU000000GMG2 GB0033877555 US66980N2036 US00704R1095 JP3778270003 GRS524003001 CA6293521051 CA04017M2031 US74982T1034 CA23344V1085 CA6410701073 US6323471002 CA6261351077 US56624R1086 ID1000186505 CA86332K4000 GB00BNYM9W73 SE0017767031 AU0000253197 GB0006389398 IL0010826357 US60871R1005 SGXE27499115 JP3040880001 CA91016A1084 CA8919571023 US3903207039 IT0005568461 US43010T1043 KYG370481080 GB00BTWSXB68 CA7739151032 CA03967C2076 US87507T1016 AU0000453185 CA2924833023 AU0000226300 AU000000OFX5 CA68621J4019 US65447N1037 CNE100007CV2 SE0017833171 KYG8123S1066 US0389238769 BMG684371393 ID1000165004 SG1Q52922370 SE0015244884 CNE1000070L0 AU000000PAR5...

23.12.25 - 10:45	GRAND PHARMA Secures Exclusive Commercialization Rights for Allergy Medicine Neffy in CN (AAStocks)
	GRAND PHARMA (00512.HK) entered into a product cooperation agreement with Pediatrix Therapeutics, as announced by GRAND PHARMA. The Group will acquire the exclusive commercialization rights in Mainland China through cooperative channels and the non-exclusive commercialization rights in Hong Kong Special Administrative Region for......

07.05.25 - 08:12	The world′s first: Grand Pharma′s global innovative product STC3141 successfully reached the clinical endpoint in the Phase II clinical study in China (PR Newswire)
	The results showed that the SOFA scores of the drug treatment groups on the 7th day were significantly lower than those of the baseline, especially in the high-dose group, where the decrease was significantly greater than that in the placebo group, of which the difference was......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das sind halt die Freuden eines Preisministers, wenn ab und zu nicht alles teurer wird. - Dr. Josef Staribacher

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram